Esperion:HC Wainwright Reiterates Buy, Raises PT to $16 from $15.50

Esperion:HC Wainwright Reiterates Buy, Raises PT to $16 from $15.50

Esperion Therapeutics, Inc. (NASDAQ: ESPR) experienced a significant 7.1% increase in its share price during mid-day trading on September 11, 2025, reaching a price of $2.79. This upward movement was despite a notable decline in trading volume, with only 1,282,316 shares traded compared to the average session volume of 4,934,244 shares.

Analysts at HC Wainwright have maintained a positive stance on Esperion Therapeutics, reaffirming their "buy" rating and raising the price target to $16.00 from the previous $15.50. This positive sentiment contrasts with other analysts who have downgraded the stock to a "hold" rating, resulting in a consensus rating of "Moderate Buy" with an average price target of $7.00 Esperion Therapeutics (NASDAQ:ESPR) Shares Up 7.1% - What's Next?^[1].

Esperion Therapeutics, a biopharmaceutical company, specializes in developing and commercializing medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its marketed products, NEXLETOL and NEXLIZET, are oral, once-daily, non-statin medicines designed to treat primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease .

In the latest quarterly earnings report, Esperion Therapeutics reported earnings per share (EPS) of $0.02, beating the consensus estimate of $0.17 by $0.15. The company also reported revenue of $82.39 million, exceeding analysts' expectations of $62.55 million. Despite these positive earnings, the company had a negative net margin of 35.84% and a negative return on equity of 0.91% .

Several institutional investors have shown interest in Esperion Therapeutics, with Sivia Capital Partners LLC, North Star Investment Management Corp., Meridian Wealth Management LLC, Synergy Asset Management LLC, and Boomfish Wealth Group LLC all increasing their stakes in the company. Institutional investors and hedge funds currently own 47.39% of the stock .